Aetna considers color-flow Doppler echocardiography in adults medically necessary for the following indications:
Aetna considers color-flow Doppler echocardiography in adults experimental and investigational for all other indications (e.g., to guide catheter ablation in ventricular tachycardia) because its effectiveness for these indications has not been established.
This policy is based on guidelines on diagnostic echocardiography in adults from the American College of Cardiology (Cheitlin et al, 2003).
Echocardiography is an ultrasound technique for diagnosing cardiovascular disorders. It is subdivided into M-mode, two-dimensional (2-D), spectral Doppler, color Doppler, contrast, and stress echocardiography (Beers and Berkow, 1999).
Echocardiography is usually performed by placing a transducer over the chest. In transesophageal echocardiography, however, the transducer is placed at the tip of an endoscope that is inserted into the esophagus (Beers and Berkow, 1999). Even smaller transducers can be placed on intravascular catheters, permitting intravascular recordings of vessel anatomy and blood flow.
Two-dimensional (or cross-sectional) echocardiography is the dominant echocardiographic technique (Beers and Berkow, 1999; Gottdiener et al, 2004). It uses pulsed, reflected ultrasound to provide spatially correct real time tomographic images of the heart, which are recorded on videotape and resemble cineangiograms. Two-dimensional echocardiography provides information about the cardiac chamber size, wall thickness, global and regional systolic function, and valvular and vascular structures. B-mode imaging refers to cross-sectional 2-D images displayed without motion, and provides detail of static structures.
M-mode (or motion-mode) echocardiography creates a continuous 1-D graphic display, and is useful for measuring single dimensions of walls and chambers of the heart, which can be used to estimate chamber volumes and left ventricular mass (Beers and Berkow, 1999; Gottdiener et al, 2004). M-mode echocardiography is performed by directing a stationary pulsed ultrasound beam at some portion of the heart.
The Doppler technique uses reflections from moving red blood cells to characterize blood flow (Beers and Berkow, 1999; Gottdiener et al, 2004). Spectral Doppler echocardiography uses ultrasound to record the velocity, direction, and type of blood flow in the cardiovascular system. The spectral Doppler signal is displayed on a strip chart recorder or videotape.
Stress echocardiography uses any combination of the above echocardiography modalities, before and during (or shortly after) a physical or pharmacological stress intervention (Beers and Berkow, 1999; Gottdiener et al, 2004). Most commonly, a treadmill or exercise bicycle is used for stress echocardiography. In patients who are unable to exercise, stress testing can be performed with pharmacological agents, such as dobutamine, that increased myocardial oxygen demand, or vasodilators that produce coronary steal. These tests have utility primarily in the detection of myocardial ischemia and viability.
Contrast echocardiography is an M-mode or 2-D echocardiographic examination during which contrast agents are administered via venous injection (Beers and Berkow, 1999; Gottdiener et al, 2004). Venous contrast injections are used to enhance left ventricular endocardial borders and Doppler signals and to assess myocardial perfusion.
Color Doppler echocardiography is essentially 2-D Doppler echocardiography with flow encoded in color to show its direction (red is toward and blue is away from the transducer) (Beers and Berkow, 1999; Gottdiener et al, 2004). In color flow mapping, blood flow velocity is measured along each sector line of a 2-D echocardiographic image and is displayed as color coded pixels. Color flow Doppler is most useful for assessing valves for regurgitation and stenosis, detecting the presence of intracardiac shunts, and imaging blood flow in the heart.
Evidence-based guidelines from the American College of Cardiology, American Heart Association, and American Society of Echocardiography (Antman et al, 2003) outlined the accepted capabilities for Doppler echocardiography in the adult patient. Specific indications were classified as relating to "anatomy-pathology" or to "function", and each potential indication was rated from "most helpful" to "not useful."
Among indications related to anatomy-pathology, color Doppler was rated as most helpful for evaluating septal defects (Antman et al, 2003). Color Doppler was considered not useful for all other indications related to anatomy-pathology: evaluation of chamber size, thickness of walls, relation of chambers, early closure of mitral valve, systolic anterior motion of mitral valve, left ventricular mass, left ventricular masses (tumor, clot, vegetation), masses in atria and right ventricle, anatomic valvular pathology, and pericardial effusion.
Among functional indications, color Doppler was considered most useful for evaluating the site of right-to-left and left-to-right shunts (Antman et al, 2003). Color Doppler was also considered useful for evaluating severity of valve stenosis and valve regurgitation and evaluation of prosthetic valves. Color Doppler was also considered to be of some use in evaluating aortic diseases. Color Doppler was considered not useful for assessment of global left ventricular systolic function (ejection fraction), evaluation of regional wall motion, measurement of right ventricular and pulmonary artery systolic pressures, measurement of left ventricular filling pressure, measurement of stroke volume and cardiac output, assessment of left ventricular diastolic function, and identifying ischemia and viable myocardium with exercise or pharmacological stress.
Nishimura et al (2011) examined the significance of measurement of stenosis by aliasing coronary flow (the MOSAIC method) for the detection of proximal left coronary stenosis in patients with unstable angina (UA) by means of transthoracic Doppler echocardiography. Patients (n = 107) with UA were evaluated. Proximal left coronary flow was sought in the short axis at the aortic root level using color Doppler guidance. When detected coronary flow showed color aliasing, the color velocity range was gradually increased until color aliasing nearly disappeared. Then, the color baseline was shifted until the color flow showed "isovelocity". Proximal coronary flow was detected in 86 (80.4 %) of 107 patients. In these 86 patients, an optimal cut-off value of isovelocity greater than or equal to 47.5 cm/second predicted significant coronary stenosis (percent diameter stenosis greater than or equal to 70 %) of the proximal left anterior descending (American Heart Association segment 6) or left main coronary artery with a sensitivity of 88 %, specificity of 97 %, positive predictive value of 98 %, and negative predictive value of 86 %. In all 107 patients, the same cut-off value predicted significant coronary stenosis with a sensitivity of 78 %, specificity of 98 %, positive predictive value of 98 %, and negative predictive value of 81 %. The authors concluded that the MOSAIC method may play a complementary role in expeditious risk stratification and decision making in patients with UA.
The American College of Radiology's Expert Panel on Cardiovascular Imaging (Ho et al, 2011) states that echocardiography using color flow Doppler is essential for evaluating blood flow as seen across an atrial defect or a ventricular septal defect or across a valve. Assessment of the valves (sclerosis, fusion, estimation of valve gradients) and determination of right ventricular systolic pressure can usually be achieved.
An UpToDate review on "Catheter ablation for ventricular arrhythmias" (Ganz, 2012) states that "[i]ntracardiac echocardiography (ICE) with 2D and Doppler color flow imaging may be useful to guide mapping and ablation catheters and monitor morphologic changes after ablation". The reference cited was the study by Ren et al (2002) that comprised only 4 patients with ventricular tachycardia. Thus, there is currently insufficient evidence to support the use of color-flow Doppler echocardiography during ventricular tachycardia ablation.
An UpToDate review on “Principles of Doppler echocardiography” (Manning, 2013) states that “Color flow imaging is typically used in the screening and assessment of regurgitant flows. It is also useful in the assessment of intracardiac shunts (e.g., atrial and ventricular septal defects) and pulmonary vein flow, and to assist in continuous wave Doppler alignment for tricuspid regurgitation velocities”.
Note on documentation requirements: Physicians are reminded to bill the findings of the diagnostic test as the primary indication rather than the referring physician’s diagnosis, as indicated by Medicare’s Diagnostic Imaging Billing guidelines. These guidelines are available at the following website: http://www.cms.hhs.gov/manuals/downloads/clm104c23.pdf. This is also indicated in the ICD-9-CM Coding Guidelines, Section IV, Paragraph L.
|CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes.  Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 2015 :|
|CPT codes covered if selection criteria are met:|
|+ 93325||Doppler echocardiography color flow velocity mapping (List separately in addition to codes for echocardiography)|
|Other CPT codes related to the CPB [parent codes for 93325]:|
|76825||Echocardiography, fetal, cardiovascular system, real time with image documentation (2D), with or without M-mode recording;|
|76826||follow-up or repeat study|
|76827||Doppler echocardiography, fetal, pulsed wave and/or continuous wave with spectral display; complete|
|76828||follow-up or repeat study|
|93303||Transthoracic echocardiography for congenital cardiac anomalies; complete|
|93304||follow-up or repeat study|
|93308||Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, follow-up or limited study|
|93312||Echocardiography, transesophageal, real time with image documentation (2D) (with or without M-mode recording); including probe placement, image acquisition, interpretation and report|
|93314||image acquisition, interpretation and report only|
|93315||Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report|
|93317||image acquisition, interpretation and report only|
|+ 93320||Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (List separately in addition to codes for echocardiographic imaging); complete|
|+ 93321||follow-up or limited study (List separately in addition to codes for echocardiographic imaging)|
|93350||Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report|
|93351||including performance of continuous electrocardiographic monitoring, with physician supervision|
|93650||Intracardiac catheter ablation of atrioventricular node function, atrioventricular conduction for creation of complete heart block, with or without temporary pacemaker placement [experimental and investigational to guide catheter ablation procedures in ventricular tachycardia]|
|93653||Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording, His recording with intracardiac catheter ablation of arrhythmogenic focus; with treatment of supraventricular tachycardia by ablation of fast or slow atrioventricular pathway, accessory atrioventricular connection, cavo-tricuspid isthmus or other single atrial focus or source of atrial re-entry [experimental and investigational to guide catheter ablation procedures in ventricular tachycardia]|
|93654||Comprehensive electrophysiologic evaluation including insertion and repositioning of multiple electrode catheters with induction or attempted induction of an arrhythmia with right atrial pacing and recording, right ventricular pacing and recording, His recording with intracardiac catheter ablation of arrhythmogenic focus; with treatment of ventricular tachycardia or focus of ventricular ectopy including intracardiac electrophysiologic 3D mapping, when performed, and left ventricular pacing and recording, when performed [experimental and investigational to guide catheter ablation procedures in ventricular tachycardia]|
|Other HCPCS codes related to the CPB::|
|C1886||Catheter, extravascular tissue ablation, any modality (insertable) [experimental and investigational to guide catheter ablation procedures in ventricular tachycardia]|
|ICD-10 codes covered if selection criteria are met:|
|A40.0 - A40.9||Streptococcal sepsis|
|A41.01 - A41.02||Sepsis due to staphylococcus aureus|
|A41.1 - A41.2||Sepsis due to other specified and unspecified staphylococcus|
|A41.3||Sepsis due to Hemophilus influenzae|
|A41.4||Sepsis due to anaerobes|
|A41.50||Gram-negative sepsis, unspecified|
|A41.51||Sepsis due to Escherichia coli [E. coli]|
|A41.52||Septicemia due to Pseudomonas|
|A41.53||Sepsis due to Serratia|
|A54.83||Gonococcal heart infection|
|B39.4 (must be billed with I32)||Histoplasmosis capsulati (pericarditis)|
|B39.4 (must be billed with I39)||Histoplasmosis capsulati (endocarditis)|
|I01.1||Acute rheumatic endocarditis|
|I01.2||Acute rheumatic myocarditis|
|I01.8||Other acute rheumatic heart disease|
|I01.9||Acute rheumatic heart disease, unspecified|
|I02.0||Rheumatic chorea with heart involvement|
|I05.0 - I05.9||Diseases of mitral valve|
|I06.0 - I06.9||Diseases of aortic valve|
|I07.0 - I07.9||Rheumatic tricuspid valve diseases|
|I08.0||Rheumatic disorders of both mitral and aortic valves|
|I09.0 - I09.89||Other rheumatic heart disease|
|I21.01 - I22.9||Acute myocardial infarction|
|I25.3||Aneurysm of heart|
|I26.09||Acute cor pulmonale|
|I32 (must be billed with B394)||Pericarditis in diseases classified elsewhere|
|I33.0 - I33.9||Acute and subacute endocarditis|
|I38 - I39||Endocarditis and heart valve disorders|
|I40.0 - I40.9||Acute myocarditis|
|I42.0 - I43||Cardiomyopathy|
|I48.0 - I48.1||Atrial fibrillation and flutter|
|I50.9||Heart failure, unspecified|
|I51.0||Cardiac septal defect, acquired|
|I51.1||Rupture of chordae tendineae, not elsewhere classified|
|I51.2||Rupture of papillary muscle, not elsewhere classified|
|I51.89||Other ill-defined heart diseases|
|I71.00 - I71.9||Aortic aneurysm and dissection|
|I95.0 - I95.9||Hypotension|
|J81.0||Acute pulmonary edema|
|M31.4||Aortic arch syndrome [Takayasu]|
|O24.011 - O24.019, O24.111 - O24.119
O24.311 - O24.319, O24.811 - O24.819
O24.911 - O24.919
|Diabetes mellitus in pregnancy|
|O33.6xx+||Maternal care for disproportion due to hydrocephalic fetus|
|O35.0xx+||Maternal care for (suspected) central nervous system malformation in fetus|
|O35.1xx+||Maternal care for (suspected) chromosomal abnormality in fetus|
|O35.2xx+||Maternal care for (suspected) hereditary disease in fetus|
|O35.3xx+||Maternal care for (suspected) damage to fetus from viral disease in mother|
|O35.4xx+||Maternal care for (suspected) damage to fetus from alcohol|
|O35.5xx+||Maternal care for (suspected) damage to fetus by drugs|
|O35.8xx+||Maternal care for other (suspected) fetal abnormality and damage|
|O35.9xx+||Maternal care for (suspected) fetal abnormality and damage, unspecified|
|O36.0110 - O36.0999||Maternal care for rhesus isoimmunizations|
|O36.1110 - O36.1999||Maternal care for other isoimmunization|
|O40.1xx+ - O40.9xx+||Polyhydramnios|
|O43.011 - O43.019||Fetomaternal placental transfusion syndrome|
|O76||Abnormality in fetal heart rate and rhythm complicating labor and delivery|
|O98.511 - O98.519||Other viral diseases complicating pregnancy|
|O98.811 - O98.819||Other maternal infectious and parasitic diseases complicating pregnancy, childbirth and the puerperium|
|O98.911 - O98.919||Unspecified maternal infectious and parasitic diseases complicating pregnancy|
|O99.411 - O99.43||Diseases of the circulatory system complicating pregnancy, childbirth and puerperium|
|P02.3||Newborn (suspected to be) affected by placental transfusion syndrome|
|P03.810||Newborn (suspected to be) affected by abnormality in fetal (intrauterine) heart rate or rhythm before the onset of labor|
|P03.819||Newborn (suspected to be) affected by abnormality in fetal (intrauterine) heart rate or rhythm unspecified as to the time of onset|
|P04.1||Newborn (suspected to be) affected by other maternal medication|
|P04.3||Newborn (suspected to be) affected by maternal use of alcohol|
|P29.3||Persistent fetal circulation|
|P70.0 - P70.1||Syndrome of infant of mother with diabetes/gestational diabetes|
|P83.2||Hydrops fetalis not due to hemolytic disease|
|Q20.0 - Q21.9||Congenital malformations of cardiac chambers, connections and septa|
|Q22.0 - Q22.3||Congenital malformations of pulmonary valves|
|Q22.4||Congenital tricuspid stenosis|
|Q23.0||Congenital stenosis of aortic valve|
|Q23.1||Congenital insufficiency of aortic valve|
|Q23.2||Congenital mitral stenosis|
|Q23.3||Congenital mitral insufficiency|
|Q23.4||Hypoplastic left heart syndrome|
|Q24.3||Pulmonary infundibular stenosis|
|Q24.4||Congenital subaortic stenosis|
|Q24.8||Other specified congenital malformations of heart|
|Q26.0 - Q26.9||Congenital malformations of great veins|
|Q86.0||Fetal alcohol syndrome (dysmorphic)|
|Q87.40 - Q87.43||Marfan's syndrome|
|R01.1||Cardiac murmur, unspecified|
|T82.01x+ - T82.09x+||Mechanical complication of heart valve prosthesis|
|T82.211+ - T82.218+||Mechanical complication of coronary bypass graft|
|T82.6xx+, T82.7xx+||Infection and inflammatory reaction due to cardiac valve prosthesis, vascular devices, implants, and grafts|
|T82.817+ - T82.9xx+||Other complications due to heart valve prosthesis|
|T86.20 - T86. 298||Complications of heart transplant|
|Z87.74||Personal history of (corrected) congenital malformations of heart and circulatory system|
|Z95.1||Presence of aortocoronary bypass graft|
|Z95.2||Presence of prosthetic heart valve|
|Z95.3||Presence of xenogenic heart valve|
|ICD-10 codes not covered for indications listed in the CPB:|